Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback